AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03822546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myblu 25 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds
Study NCT03822546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: myblu 40 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds
Study NCT03822546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blu PRO 48 mg nicotine salt
Description: E-cigarette used for 10 inhalations every 30 seconds
Study NCT01339104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
Study NCT02705755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-9855
Description: Administered orally.
Study NCT02705755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT03105375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending dose of X842
Description: Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
Study NCT03105375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending dose of X842
Description: Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
Study NCT03105375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losec
Description: Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
Study NCT03906591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogenic bone ring
Description: allogenic bone ring with simultaneous dental implant placement
Study NCT03906591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autogenous bone ring
Description: autogenous bone ring with simultaneous dental implant placement
Study NCT03809078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga RM2
Description: PET radiopharmaceutical
Study NCT03809078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: PET radiopharmaceutical
Study NCT01181362 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopy
Description: All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
Study NCT02647372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus
Description: Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
Study NCT03957070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver Incyte
Description: Ultrasound elasticity imaging
Study NCT00593151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locteron (controlled-release interferon alpha 2b)
Description: biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
Study NCT03809078 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational PET scanner coils and software
Description: GE Healthcare non-approved PET scanner coils and software
Study NCT01707680 — intervention group
Intervention type: OTHER
Intervention: SOC
Description: Patient are given standard of care
Study NCT02654821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR transduced T-cells
Description: Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
Study NCT02654821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
Study NCT02654821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood taking
Description: During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
Study NCT05435131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GCF obtaining
Description: GCF obtaining: 2 GCF samples, 1 from the interproximal surface of 2 different teeth that bleeding on probing(-), were taken from each participant
Study NCT00588471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
Study NCT00588471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
Study NCT02275611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intranasal oxytocin spray
Description: Administration of oxytocin in a nasal spray
Study NCT02275611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal oxytocin spray
Description: Administration of oxytocin in a nasal spray
Study NCT02275611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo Spray
Description: Intranasal Placebo Spray
Study NCT01747798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: auranofin
Description: Given PO
Study NCT01747798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02379936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Neo Hilda
Description: This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method
Study NCT00847860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Cilostazol 100 mg bid for 12 months
Study NCT00847860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 100 mg qd for 12 months
Study NCT02379936 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional evaluation
Description: Traditional way of evaluation
Study NCT02379936 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPhone 4S
Study NCT02477514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: 2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
Study NCT02477514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 10 mg tablet administered as a single oral dose on Days 3 and 16
Study NCT02477514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tedizolid phosphate
Description: 200 mg oral tablet administered once daily on Days 5-17
Study NCT03417479 — intervention group
Intervention type: OTHER
Intervention: Gabapentin
Study NCT03717467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Study NCT03717467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: 40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
Study NCT00176202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex sodium is a mood stabilizer
Study NCT02647372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Globus pallidus
Description: Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
Study NCT02481323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isosorbide mononitrate
Description: slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
Study NCT02481323 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: isosorbide mononitrate
Description: slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
Study NCT02481323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
Study NCT02481323 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cilostazol
Description: phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
Study NCT03445611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid solution with lidocaine containing parabens.
Description: To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
Study NCT03445611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid solution with lidocaine containing no paraben
Description: To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
Study NCT03017040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT scan
Description: A CT scan of the wrist
Study NCT03017040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan
Description: A CT scan of the wrist
Study NCT03017040 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy Scan
Description: A fluoroscopy scan of the wrist.
Study NCT03017040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoroscopy Scan
Description: A fluoroscopy scan of the wrist.
Study NCT03455634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block
Description: functional appliances for the stimulation of the mandibular growth
Study NCT03455634 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sander bite jumping appliance
Description: functional appliances for the stimulation of the mandibular growth
Study NCT03628040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Injection [Naropin]
Description: Ropivacaine will be injected in the erector spinae plane
Study NCT03628040 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be injected in the erector spinae plane
Study NCT01657227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to patients
Description: Multifaceted intervention consisting of:~* Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~* Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~* Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change.
Study NCT01657227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to professionals
Description: Multifaceted intervention consisting of:~* Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~* Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~* Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional.
Study NCT01657227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care for T2DM received in primary health care
Study NCT01657227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care for T2DM received in primary health care
Study NCT00433927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
Study NCT00433927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
Study NCT00433927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan
Description: Irinotecan 180 mg/m² iv, 30 - 90 min day 1
Study NCT00433927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
Study NCT00433927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
Study NCT04573491 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic test
Description: genotyping for genes that affect drug metabolism
Study NCT04573491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication review
Description: systematic and interdisciplinary method aiming to increase quality of medication treatment
Study NCT00993980 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: qigong
Description: one therapy session once a week during three months, that is 12 therapy sessions altogether
Study NCT00993980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: one therapy session once a week during three months, that is 12 therapy sessions altogether
Study NCT02828189 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 9 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
Study NCT02828189 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Education
Description: Individual Therapeutic Education about healthy habits and exercise on breast cancer.
Study NCT02828189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: Individual Therapeutic Education about healthy habits and exercise on breast cancer.
Study NCT02828189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise-Physiotherapy
Description: 1. Cardiovascular exercise~2. Individualized progressive strength and resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk.~3. Flexibilization exercises
Study NCT02827487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
Study NCT02827487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
Study NCT02827487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 1
Description: Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
Study NCT02827487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1
Description: Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
Study NCT02827487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 2
Description: Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
Study NCT02827487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
Study NCT05435131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva Obtaining
Description: Saliva obtaining: 1,5 ml unstimulated whole saliva collected from each participant
Study NCT00176202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Risperidone is a second generation antipsychotic and antimanic drug
Study NCT03058445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
Study NCT03058445 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVC
Description: Injection of 5 ml of saline
Study NCT02189174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR457
Study NCT02827487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUD
Description: IUD insertion
Study NCT02827487 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IUD
Description: IUD insertion
Study NCT02574520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SABER-Bupivacaine (Part 1)
Description: 5 ml once at end of surgery
Study NCT02574520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SABER-Bupivacaine (Part 2)
Description: 5 ml once at end of surgery
Study NCT02574520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 5 ml once at end of surgery
Study NCT00593151 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegylated IFNa2b
Description: biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
Study NCT02574520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: 0.5%, 15 ml, once at end of surgery
Study NCT01424306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose-sweetened beverages
Description: In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
Study NCT01424306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-sweetened beverages
Description: In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
Study NCT01424306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fructose corn syrup-sweetened beverages
Description: In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
Study NCT03993301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic A formula
Description: Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.
Study NCT03993301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic B formula
Description: Feeding baby two meals a day with Infant formula with probiotics (10\^8 colony-forming unit per day) at least.